-
-
-
-
-
-
-
CorMedix (CRMD) PT Raised to $14 at RBC Capital
-
-
-
-
-
-
-
CorMedix (CRMD) PT Lowered to $15 at Leerink Partners
-
-
-
-
-
-
-
CorMedix raises 2025 revenue guidance to at least $375 million
-
-
-
-
-
-
-
CorMedix to acquire Melinta Therapeutics for $300 million
-
-
-
-
-
-
-
CorMedix (CRMD) announces $85 million public offering
-
-
-
-
-
-
-
CorMedix (CRMD) Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
-
-
-
-
-
-
-
CorMedix (CRMD) Added to Nasdaq Biotechnology Index
-
459,818 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

